# Phase 6: Go/No-Go Recommendation

**Date:** July 15, 2026
**Review Board:** Haspataal Architecture Committee
**Project Phase:** Phase 6 (MVP Launch Readiness)

## Executive Summary
After rigorous execution of the Phase 6 Production Hardening Sprint—encompassing Security, Performance, Reliability, Billing Validation, Load Testing, and a full Regression Matrix—the platform demonstrates robust stability and architectural integrity.

## Assessment Matrix
1. **Security & Privacy:** PASS (0 critical vulnerabilities; DPDP / encryption verified).
2. **Performance:** PASS (P95 < 300ms across all core endpoints).
3. **Reliability & Eventing:** PASS (Idempotency and outbox replays function correctly).
4. **End-to-End Workflows:** PASS (Canonical order separation holds true with zero clinical mutation).
5. **Billing Integration:** PASS (Zero discrepancies in IPD/OPD/Pharmacy/Diagnostics).
6. **Deployment & DR:** PASS (Zero downtime deployment and DB recovery tested).

## Final Recommendation
**STATUS: GO 🟢**

The Haspataal MVP is formally recommended for deployment to the first pilot hospital. The foundational architecture (RLS, RBAC, Event Sourcing, Canonical Engines) has proven highly resilient under load. No outstanding blockers remain.
